Kenneth Ssebambulidde, MBChB, MSc
Hospital ResidentCards
About
Titles
Hospital Resident
Biography
Dr. Kenneth Ssebambulidde, MBChB, MSc, is an Internal Medicine resident in the Primary Care Program at Yale School of Medicine. He earned his medical degree from Makerere University in Uganda, where he graduated at the top of his class, and completed a Master of Science in Immunology of Infectious Diseases with distinction at the London School of Hygiene & Tropical Medicine. Before joining Yale, he completed his preliminary Internal Medicine residency at Howard University Hospital in Washington DC, where he was recognized as the Best Preliminary Internal Medicine Resident for outstanding clinical excellence, professionalism, and dedication to patient care. He had previously served as a Visiting Postdoctoral Fellow in the Laboratory of Clinical Immunology and Microbiology at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health in Bethesda, Maryland, where he investigated the immunopathogenesis of non-HIV-associated cryptococcal meningitis and fungal post-infectious inflammatory syndrome.
Dr. Ssebambulidde's academic interests span infectious diseases, immunology, health outcomes research, and primary care. His research has focused on central nervous system infections, HIV-associated opportunistic infections, host immune responses, and translational immunology, with work contributing to studies that have informed international/WHO treatment guidelines. More recently, he has expanded his scholarship to real-world clinical outcomes research using large multicenter databases, collaborating with residents and fellows across multiple specialties. He has co-authored more than 70 peer-reviewed publications in journals including The New England Journal of Medicine, Nature Reviews Disease Primers, Nature Communications, Science Advances, Clinical Infectious Diseases, and The Lancet Infectious Diseases, and has received several national and international awards recognizing his contributions to clinical and translational research.
At Yale, Dr. Ssebambulidde aims to integrate compassionate primary care with clinical investigation to improve outcomes for patients with complex chronic conditions. His long-term career goal is to become a physician-scientist dedicated to advancing patient care through translational research, mentorship, and medical education.
Departments & Organizations
Education & Training
- Internship
- Howard University (2026)
- Visiting Fellow
- National Institute of Allergy and Infectious Disease (2025)
- MSc
- London School of Hygiene & Tropical Medicine, Immunology of Infectious Diseases (2019)
- Internship
- St. Francis Hospital - Nsambya (2016)
- MBChB
- Makerere University College of Health Sciences (2015)
Research
Publications
2026
Central Nervous System Toxoplasmosis is an Under‐Recognized Opportunistic infection in Uganda
Bahr NC, Kasibante J, Nsangi L, Kagimu E, Ssebambulidde K, Rutakingirwa MK, Tugume L, Ramachandran PS, Cresswell F, Meya DB, Boulware DR, Wilson MR, Ellis J. Central Nervous System Toxoplasmosis is an Under‐Recognized Opportunistic infection in Uganda. Journal Of Tropical Medicine 2026, 2026: 2158978. DOI: 10.1155/jotm/2158978.Peer-Reviewed Original ResearchGLP-1 receptor agonists and clinical outcomes in adults with Crohn’s disease and obesity: a propensity score–matched real-world cohort study
Ganju N, Ssebambulidde K, Gupta S, Adidam SR, Michael M, Kibreab A, Aduli F. GLP-1 receptor agonists and clinical outcomes in adults with Crohn’s disease and obesity: a propensity score–matched real-world cohort study. Scientific Reports 2026 DOI: 10.1038/s41598-026-58181-y.Peer-Reviewed Original Research
2025
Correlates of HIV pre- and post-exposure prophylaxis uptake among female university students in Uganda
Segawa I, Bakeera-Kitaka S, Oriokot L, Ssebambulidde K, Muwonge T, Ojiambo K, Mujugira A. Correlates of HIV pre- and post-exposure prophylaxis uptake among female university students in Uganda. African Journal Of AIDS Research 2025, 24: 197-204. PMID: 41031422, DOI: 10.2989/16085906.2025.2555200.Peer-Reviewed Original ResearchConceptsHIV pre-Post-exposure prophylaxis uptakeUptake of PrEPHigh-risk sexual behaviorSexual assaultTransactional sexHIV riskPost-exposure prophylaxisLow uptakeUnprotected sexPEP useSexual behaviorFemale university studentsSexual intercoursePrEPHIVUnknown statusUgandaFemale studentsPublic universityMakerere UniversitySexUniversity studentsAssaultOnline surveyCerebrospinal Fluid Mononuclear Cell Phenotype and Activation Predictors of 2-Week and 1-Year Survival Among Persons With HIV-Associated Cryptococcal Meningitis
Rutakingirwa M, Ssebambulidde K, Okurut S, Kwizera R, Nabwana M, Gakuru J, Ndyetukira J, Mulwana S, Nankungu L, Tadeo K, Musubire A, Boulware D, Meya D. Cerebrospinal Fluid Mononuclear Cell Phenotype and Activation Predictors of 2-Week and 1-Year Survival Among Persons With HIV-Associated Cryptococcal Meningitis. Journal Of Infectious Diseases 2025, 232: 1088-1096. PMID: 40839770, PMCID: PMC12614965, DOI: 10.1093/infdis/jiaf449.Peer-Reviewed Original ResearchConceptsHIV-associated cryptococcal meningitisCryptococcal meningitisMononuclear cell phenotypesCerebrospinal fluidImmune exhaustionCD56+ natural killer cellsCerebrospinal fluid T lymphocytesCrAg lateral flow assayCD8+ T cellsCerebrospinal fluid CrAg-HIV-associated CMPD-1 expressionCell phenotypeRisk of early mortalityCellular immune phenotypesCD14+ macrophagesCSF mononuclear cellsNatural killer cellsCD14+ monocytesYear of treatmentFrozen cerebrospinal fluidExpression of CD163CrAg titersCSF CrAgPD-1Cerebral Perfusion Pressures and Implications on Clinical Outcomes and Medical Management in Cryptococcal Meningitis
Abassi M, Hou C, Fieberg A, Dai B, Musubire A, Robertson J, Tugume L, Ssebambulidde K, Nuwagira E, Muzoora C, Williams D, Boulware D, Meya D, Mpoza E, Kiggundu R, Pastick K, Ssebambulidde K, Akampurira A, Williams D, Bangdiwala A, Musubire A, Nicol M, Ahimbisibwe C, Kugonza F, Namuju C, Tadeo K, Kirumira P, Okirwoth M, Luggya T, Kaboggoza J, Laker E, Walukaga S, Evans E, Stadelman A, Flynn A, Fujita A, Kwizera R, Lofgren S, Cresswell F, Morawski B. Cerebral Perfusion Pressures and Implications on Clinical Outcomes and Medical Management in Cryptococcal Meningitis. Open Forum Infectious Diseases 2025, 12: ofaf451. PMID: 40832594, PMCID: PMC12359033, DOI: 10.1093/ofid/ofaf451.Peer-Reviewed Original ResearchMean arterial pressureCerebral perfusion pressureCryptococcal meningitisIntracranial pressureClinical outcomesIntracranial hypertensionProspective cohortHIV-associated cryptococcal meningitisPerfusion pressureBaseline cerebral perfusion pressureNormal mean arterial pressureAssociated with worse outcomesLow mean arterial pressureMean arterial pressure groupsLow cerebral perfusion pressureHigher mean arterial pressureCerebral perfusion pressure levelIntracranial pressure measurementsClinical presentationClinical profileCerebral hyperperfusionWorse outcomesClinical managementArterial pressureUgandan adultsPathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome
Hargarten J, Ssebambulidde K, Anjum S, Vaughan M, Xu J, Ganguly A, Dulek B, Otaizo-Carrasquero F, Song B, Tao S, Park Y, Scott T, Höltermann T, Schinazi R, Chittiboina P, Billioux B, Hammoud D, Olszewski M, Williamson P. Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome. Science Advances 2025, 11: eadi9885. PMID: 40117367, PMCID: PMC11927619, DOI: 10.1126/sciadv.adi9885.Peer-Reviewed Original ResearchConceptsCentral nervous systemRuxolitinib treatmentClinical studiesCerebral spinal fluid samplesMarker of neuronal damageInflammatory response syndromeAcute central nervous systemTreatment of patientsJAK inhibitor ruxolitinibSpinal fluid samplesJanus kinase/signal transducer and activatorInflammatory syndromeResponse syndromeT cellsCryptococcal meningoencephalitisMyeloid cellsImmune cellsInhibitor ruxolitinibInflammatory biomarkersJAK inhibitorsGene signatureRuxolitinibNeuronal damagePatientsNeuroinflammatory diseasesImpact of cerebrospinal fluid leukocyte infiltration and activated neuroimmune mediators on survival with HIV-associated cryptococcal meningitis
Okurut S, Boulware D, Manabe Y, Tugume L, Skipper C, Ssebambulidde K, Rhein J, Musubire A, Akampurira A, Okafor E, Olobo J, Janoff E, Meya D, Team F. Impact of cerebrospinal fluid leukocyte infiltration and activated neuroimmune mediators on survival with HIV-associated cryptococcal meningitis. PLOS Neglected Tropical Diseases 2025, 19: e0012873. PMID: 39928682, PMCID: PMC11844869, DOI: 10.1371/journal.pntd.0012873.Peer-Reviewed Original ResearchConceptsHIV-associated cryptococcal meningitisCryptococcal meningitisLeukocyte infiltrationAdvanced HIV diseaseInduction therapyCSF leukocytesHIV diseaseCytokine responsesImmune responseNeuroimmune mediatorsMeningitisCSFSurvivalInfiltrationFluconazoleAmphotericinChemokinesTherapyCytokinesNeuroimmuneLeukocytesWeeksDiseaseP-922. Intracranial Pressure Phenotypes and Mortality Among People Treated for HIV-Related Cryptococcal Meningitis in Uganda
Schwartz E, Liu M, Kagimu E, Nuwagira E, Tugume L, Ssebambulidde K, Turyasingura I, Kasozi D, Kigozi E, Okurut S, Musubire A, Skipper C, Abassi M, Fieberg A, Muzoora C, Meya D, Boulware D. P-922. Intracranial Pressure Phenotypes and Mortality Among People Treated for HIV-Related Cryptococcal Meningitis in Uganda. Open Forum Infectious Diseases 2025, 12: ofae631.1113. PMCID: PMC11778016, DOI: 10.1093/ofid/ofae631.1113.Peer-Reviewed Original ResearchCryptococcal meningitisElevated ICPComplication of cryptococcal meningitisHIV-related cryptococcal meningitisCerebrospinal fluidAdvanced HIV diseaseOpening pressureTherapeutic lumbar punctureHIV-related deathsClinical management needsElevated intracranial pressureFollow-up time frameCSF OPSurvival benefitHIV diseaseLumbar puncturePoor prognosisMeningitisIntracranial pressureRisk factorsClinical implicationsMortalityNormal phenotypeHIVPhenotypeNeurocognitive Impairment Among Cryptococcal Meningitis Survivors in Uganda, a Prospective Cohort Study
Nsangi L, Hullsiek K, Dai B, Namudde A, Menya G, Ssebambulidde K, Tugume L, Nuwagira E, Rhein J, Williams D, Musubire A, Boulware D, Meya D, Abassi M. Neurocognitive Impairment Among Cryptococcal Meningitis Survivors in Uganda, a Prospective Cohort Study. Open Forum Infectious Diseases 2025, 12: ofaf054. PMID: 40008306, PMCID: PMC11850114, DOI: 10.1093/ofid/ofaf054.Peer-Reviewed Original ResearchGlasgow Coma Scale scoreComa Scale scoreSevere neurocognitive impairmentNeurocognitive impairmentMeningitis survivorsCryptococcal meningitisScale scoreHIV-associated cryptococcal meningitisReference cohortModerate neurocognitive impairmentProspective cohort studyAssociated with worse neurocognitive performanceWeeks post-treatmentAstro-CMNeurocognitive performance scoresBaseline demographicsLaboratory variablesCohort studyUgandan adultsZ-scoreLt;15Neurocognitive outcomesSevere impairmentWeeksMeningitis
2024
The evolution of HIV-associated cryptococcal meningitis in Uganda from 2010 to 2022
Walukaga S, Fieberg A, Musubire A, Tugume L, Ssebambulidde K, Kagimu E, Kasibante J, Rutakingirwa M, Mpoza E, Gakuru J, Akampurira A, Jjunju S, Mwesigye J, Muzoora C, Nuwagira E, Bangdiwala A, Williams D, Rhein J, Meya D, Boulware D, Hullsiek K, Rajasingham R, Ndyetukira J, Ahimbisibwe C, Kugonza F, Namuju C, Sadiq A, Namudde A, Mwesigye J, Cresswell F, Kandole T, Kirumira P, Okirwoth M, Luggya T, Kwizera R, Mukaremera L, Lofgren S, Stadelman A, Morawski B, Rolfes M, Wiesner D, Najjuka G, Nanteza C, Mushagara R, Bahr N, Namawejje M, Ssennono M, Kiragga A, Taseera K, Nabeta H. The evolution of HIV-associated cryptococcal meningitis in Uganda from 2010 to 2022. Medical Mycology 2024, 63: myae115. PMID: 39779301, PMCID: PMC11718514, DOI: 10.1093/mmy/myae115.Peer-Reviewed Original ResearchConceptsHIV-associated cryptococcal meningitisCryptococcal meningitisTwo-week mortalityAntiretroviral therapyClinical outcomesProspective cohortMedian CD4 cell countCerebrospinal fluidCD4 cell countHIV-infected UgandansClinical outcomes of peopleAIDS-related deathsLow cerebrospinal fluidSeverely ill populationART-naiveTwo-weekAntifungal therapyClinical presentationQuantitative culturesBaseline demographicsClinical characteristicsLumbar punctureHIV program implementersClinical trialsMeningitis
Academic Achievements & Community Involvement
Get In Touch
Contacts
Yale School of Medicine
20 York Street
New Haven, CT 06510-3220
United States